The U.S. National Cancer Institute (NCI) has awarded a $1,245,116 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Emory University in Atlanta, Georgia, to enhance cervical cancer screening and treatment services for women living with HIV in Kenya. The project, titled "ENHANCING CERVICAL CANCER SCREENING AND TREATMENT IN WOMEN LIVING WITH HIV IN KENYA (ENHANCE LINKAGE)," aims to employ rigorous implementation science methods to adapt and test strategies...
The U.S. National Cancer Institute (NCI) awarded a $1,638,000 Project Grant under the Federal Grant Program for Cancer Treatment Research (CFDA 93.395) to the University of Colorado-Denver. The grant will fund a 6-year longitudinal study investigating the effects of HIV infection on the oral environment and its impact on the reactivation and shedding of Kaposi's sarcoma-associated herpesvirus (KSHV) in the oral cavity of Ugandan adults. The study aims to determine whether markers of oral...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,456,920 to fund the development and validation of a point-of-care breast cancer diagnostic kit tailored for primary care clinics in Uganda. The project aims to optimize, validate, and deploy a novel diagnostic kit that combines an automated AI-enabled whole breast ultrasound and a smartphone-enabled AI-powered device for cytology and...
The National Cancer Institute (NCI) awarded a $643,363 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Tulane University. The project, titled "A Hybrid Type III Effectiveness-Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique," will test implementation best practices for deploying a screen and treat approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and...
The U.S. National Cancer Institute (NCI) awarded a $632,241 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University to implement the "Liver Cancer Comprehensive Control (LC3) Package" in Uganda. This award leverages the longstanding partnership between Makerere and Johns Hopkins Universities to integrate hepatitis B virus (HBV) screening, diagnosis, and treatment services into existing HIV care delivery platforms. The key products...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The funding will be used to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMICs). Specifically, the project aims to:...
The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $400,000 Project Grant to Argosmd, Inc. to develop a low-cost, non-invasive Mini-Reflectance Confocal Microscope (Mini-RCM) device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging Mini-RCM that can enable rapid examination of multiple skin lesions, addressing limitations of the current high-cost, cart-based reflectance confocal...
This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program, supports research to develop new cell culture models for studying Kaposi's sarcoma, a cancer caused by the Kaposi's sarcoma-associated herpesvirus (KSHV). The $411,400 award to Northwestern University will be used to identify KSHV-induced human genes that promote the loss of contact inhibition of proliferation in KSHV-infected lymphatic endothelial cells (KLECs), a...
The National Cancer Institute (NCI) awarded a $599,191 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Diego (UCSD) to develop and validate new perfusion measurement techniques using 3D Dynamic Contrast-Enhanced Ultrasound (3D DCE-US) imaging. The goal is to characterize complex tumor vascular properties and detect microvascular changes following cancer therapy, with the aim of improving non-invasive bedside diagnostics and treatment...
The National Cancer Institute (NCI) has awarded a $1,837,497 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to New York University to implement the KUPEWA project. The goal of the project is to identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for adolescent girls and young women living with HIV in Malawi. The study will use the Theoretical Domains Framework and WHO's Behavioural and Social Drivers of Vaccination...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,729,890 Cooperative Agreement to The Washington University to develop and validate a new medical imaging technology, called SkinScan3D, for improved Kaposi Sarcoma (KS) treatment monitoring in East Africa. The project, titled "PRIME-KS", involves refining the SkinScan3D device, assessing its accuracy and reproducibility compared to standard-of-care methods, and evaluating its integration into clinical workflows in Uganda and Kenya. Sub-awardees Pensievision, Inc. and the Infectious Diseases Institute in Uganda will provide technical development, user-centered design, and implementation support for the SkinScan3D technology. The overall goal is to enable more precise, equitable, and rapid KS treatment response assessment, leading to improved patient outcomes and reduced treatment-related toxicities in this vulnerable population.